- Home
- YETI vs ADPT Comparison
YETI vs ADPT Comparison
Compare YETI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YETI
- ADPT
- Stock Information
- Founded
- YETI 2006
- ADPT 2009
- Country
- YETI United States
- ADPT United States
- Employees
- YETI N/A
- ADPT N/A
- Industry
- YETI Recreational Games/Products/Toys
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YETI Consumer Discretionary
- ADPT Health Care
- Exchange
- YETI Nasdaq
- ADPT Nasdaq
- Market Cap
- YETI 2.7B
- ADPT 2.6B
- IPO Year
- YETI 2018
- ADPT 2019
- Fundamental
- Price
- YETI $32.68
- ADPT $17.26
- Analyst Decision
- YETI Buy
- ADPT Strong Buy
- Analyst Count
- YETI 13
- ADPT 10
- Target Price
- YETI $38.83
- ADPT $15.10
- AVG Volume (30 Days)
- YETI 1.4M
- ADPT 1.6M
- Earning Date
- YETI 11-06-2025
- ADPT 11-05-2025
- Dividend Yield
- YETI N/A
- ADPT N/A
- EPS Growth
- YETI N/A
- ADPT N/A
- EPS
- YETI 2.10
- ADPT N/A
- Revenue
- YETI $1,822,000,000.00
- ADPT $205,216,000.00
- Revenue This Year
- YETI $3.23
- ADPT $34.41
- Revenue Next Year
- YETI $5.13
- ADPT $14.03
- P/E Ratio
- YETI $15.99
- ADPT N/A
- Revenue Growth
- YETI 3.63
- ADPT 21.60
- 52 Week Low
- YETI $26.61
- ADPT $4.27
- 52 Week High
- YETI $45.25
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- YETI 38.61
- ADPT 61.72
- Support Level
- YETI $34.50
- ADPT $16.59
- Resistance Level
- YETI $36.56
- ADPT $17.76
- Average True Range (ATR)
- YETI 1.01
- ADPT 0.77
- MACD
- YETI -0.16
- ADPT -0.08
- Stochastic Oscillator
- YETI 1.77
- ADPT 62.06
About YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).